You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

504 Results
This hub contains tools and resources for primary care providers, colposcopists and other health care providers. This material supports the Ontario...
Guidelines and Advice
Status: Current
Version: 1
Updated
Nov 2025
Drug
Other Name(s): Darzalex®
Jan 2026
Drug
Other Name(s): Darzalex® SC
Jan 2026
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Jan 2026
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
New Drug Funding Program
    Daratumumab in Combination with a Bortezomib-Based Regimen for Newly Diagnosed Transplant Ineligible Multiple Myeloma
Jan 2026
Regimen
Cancer Type:
Hematologic, 
Amyloidosis, 
Multiple Myeloma
Intent: Palliative
Funding:
New Drug Funding Program
    Daratumumab in Combination with a Bortezomib-Based Regimen for Newly Diagnosed Transplant Ineligible Multiple Myeloma
New Drug Funding Program
    Daratumumab - In Combination with Bortezomib and Dexamethasone for Relapsed Multiple Myeloma
New Drug Funding Program
    Daratumumab and Bortezomib in combo with Cyclophosphamide and Dexamethasone - Previously Untreated Light Chain (AL) Amyloidosis
Jan 2026
Drug
Other Name(s): Cosmegen®
Feb 2026
Symptom Management
Symptom Management
Drug
Other Name(s): Nubeqa®
Feb 2026

Pages